Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
April 29, 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024.
Arcutis Appoints David Topper as Chief Financial Officer
April 10, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that David Topper has been appointed Chief Financial Officer effective April 10, 2024.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
March 28, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that Arcutis management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024.
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
March 11, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the promotion of Todd Tucker to senior vice president and Chief Human Resources Officer.
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
March 10, 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
March 09, 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
These findings are the first to characterize the unique molecular profile of seborrheic dermatitis
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
March 04, 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the closing of its previously announced underwritten public offering.
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
March 04, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced five presentations at the 2024 American Academy of Dermatology (AAD) annual meeting.